Pascal Soriot (AstraZeneca via YouTube)
February 11, 2021 05:39 AM ESTUpdated February 12, 04:50 AM
R&D

As US da­ta for Covid-19 vac­cine loom, As­traZeneca cleans house and scraps sev­er­al asth­ma, can­cer drugs from pipeline

Amber Tong

Just a week af­ter re­veal­ing an­oth­er flop for its PD-1/CT­LA-4 strat­e­gy, As­traZeneca has scrapped plans for the Imfinzi/treme­li­mum­ab com­bo in head and neck can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times